Shingrix vaccine and very rare risk of Guillain-Barré Syndrome

News Healthcare & Pharma Reports

Date: 29th Oct, 2024 Source: Therapeutic Goods Administration (TGA) Country: Australia Original Source

Brief

On 29/10/2024, the Therapeutic Goods Administration (TGA) issued an update regarding Shingrix vaccine and very rare risk of Guillain-Barré Syndrome. The TGA has updated the Product Information (PI) and Consumer Medicine Information (CMI) documents for Shingrix to reflect new reporting data on Guillain-Barré Syndrome, a rare immune disorder in which the body's immune system attacks nerve cells.

This content is restricted.

Highlights content goes here...

This content is restricted.

Therapeutic Goods Administration (TGA)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

Shingrix vaccine and very rare risk of Guillain-Barré Syndrome

Brief

Therapeutic Goods Administration (TGA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

Shingrix vaccine and very rare risk of Guillain-Barré Syndrome

Brief

Therapeutic Goods Administration (TGA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.